Ambrx Inc logo

AMBX - Ambrx Inc Share Price

n/a 0.0  0.0%

Last Trade -

Sector
Healthcare
Size
Micro Cap
Market Cap £n/a
Enterprise Value £n/a
Revenue £15.1m
Position in Universe th / 6415
Bullish
Bearish
Unlock AMBX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

AMBX Revenue Unlock AMBX Revenue

Net Income

AMBX Net Income Unlock AMBX Revenue

Normalised EPS

AMBX Normalised EPS Unlock AMBX Revenue

PE Ratio Range

AMBX PE Ratio Range Unlock AMBX Revenue

Dividend Yield Range

AMBX Dividend Yield Range Unlock AMBX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AMBX EPS Forecasts Unlock AMBX Revenue
Profile Summary

Ambrx Inc. is a biopharmaceutical company. The Company delivers protein therapeutics using an expanded genetic code. The Company has product candidates at various stages of development in its pipeline, with a focus on discovering and developing biopharmaceutical product opportunities. It also has partnerships with assets at various stages of development. Its portfolio includes Ambrx ADC and Bi-Specific Product Candidates, such as ARX788 αHER2 ADCHER2+Breast Cancer, PSMA ADC-Oncology, CD70 ADC-Oncology, Bi-specific Anti-CD3 X Folate and CD184 ADC Oncology; Ambrx Long-Acting Protein Product Candidates, including ARX328 LeptinLipodystrophy/Weight Mgmt; COLLABORATION Product and Product Candidates, such as ARX618 FGF21Diabetes, ARX720 RelaxinHeart Failure, Imrestor-Mastitis in Cattle, and other early-stage programs, among others. The Company's Ambrx technology combines site-specific conjugation with linkers, payloads and pharmacokinetic extenders to create a single molecular species.

Directors
Last Annual December 31st, 2013
Last Interim March 31st, 2014
Incorporated January 31, 2003
Public Since June 25, 2014
No. of Shareholders: n/a
No. of Employees: 74
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange NASDAQ Global Select Market
Shares in Issue 17,171,371
Free Float (0.0%)
Eligible for
ISAs
SIPPs
AMBX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AMBX
Upcoming Events for AMBX
Similar to AMBX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.